Zhi Tong Cai Jing·2025-09-05 07:37Core Viewpoint - The pharmaceutical sector is experiencing a significant structural recovery after a prolonged valuation adjustment, with public fund holdings still below historical averages, and the policy environment in 2025 expected to support commercial insurance development, leading to marginal improvements in payment systems and benefits for innovative drugs and devices [1] Group 1: Industry Performance - In the first half of 2025, the pharmaceutical industry's revenue decreased by 0.7%, while net profit attributable to shareholders grew by 1.5%, indicating a mixed performance influenced by macroeconomic changes and healthcare cost control pressures [1] - The pharmaceutical industry is facing structural differentiation, with the chemical preparation sector undergoing innovation transformation and the R&D outsourcing services showing strong performance [1][2] - The average gross margin for the pharmaceutical industry in the first half of 2025 was 48.7%, and the average net profit margin was 15.1%, both reflecting a decline compared to the previous year [2] Group 2: Investment Opportunities - The innovative drug sector is expected to continue its growth, with major products like Zebutinib and Furmonertinib exceeding sales expectations, leading to profitability for leading companies such as BeiGene and Innovent Biologics [3] - The recovery in the secondary market is anticipated to drive an increase in investment in the primary market, particularly benefiting CXO and upstream sectors [1] - The medical device sector is showing signs of recovery, with improved bidding data and the gradual release of pent-up demand [1] Group 3: Market Valuation - As of September 3, 2025, the rolling P/E ratio for the pharmaceutical industry was 40.74, significantly higher than the 14.14 for the CSI 300, indicating a premium of 188.09% over the CSI 300 [4] - The SW pharmaceutical and biotechnology index increased by 1.63% from early 2023 to September 3, 2025, underperforming the CSI 300, which rose by 15.98%, resulting in a relative underperformance of 14.35% [4]